Efficacy of Bedaquiline in the Management of Multidrug-Resistant Tuberculosis in the Central African Republic
Abstract
Multidrug-resistant tuberculosis (MDR-TB) poses a major challenge in the Central African Republic (CAR), as the high incidence of tuberculosis and resistance rates to anti-tuberculosis drugs compromise efforts to manage MDR/RR-TB patients. This study evaluates the efficacy of bedaquiline, integrated into the short BPaLM regimen (Bedaquiline-Pretomanid-Linezolid-Moxifloxacin), in 68 patients with MDR-TB or pre-extensively drug-resistant (pre-XDR) TB. Strains from the National Reference Laboratory of Bangui underwent whole-genome sequencing and in silico resistance analysis. Among the participants (mean age: 32 years; 60.29% male), 82.35% had MDR-TB and 4.42% had pre-XDR TB. All strains were sensitive to bedaquiline, with no mutation detected in the atpC gene. Of the 59 patients treated, 57 (96.6%) successfully completed the 9-month protocol, confirmed by a negative culture at month 21. Two deaths, occurring before the start of treatment (due to a drug stockout), were not attributable to the treatment regimen. These results demonstrate exceptional efficacy of bedaquiline in a real-world setting, with a 100% therapeutic success rate among patients who received the treatment. The study underscores the importance of continuous access to medications and supports adopting the BPaLM regimen in CAR to improve MDR/RR-TB management. These findings support the integration of bedaquiline into national strategies, aligned with WHO objectives for tuberculosis elimination.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.